Cha Albert — SEC insider filings
SEC reporting owner CIK 1397906. 8 insider filings on record with FilingPulse; latest filed 2026-10-15.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2020-10-02 to 2026-10-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 415,686 shares, $4,994,068 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 18,000 shares, $189,050 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: purchase of 300,000 shares @ $10.00 ($3,000,000) in Frazier Life Sciences Acquisition Corp. II, filed 2026-10-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Frazier Life Sciences Acquisition Corp. II (FLSC) | Chief Executive Officer, Director, 10% owner | 2 | 1 leg · 300,000 sh · $3,000,000 | — | — |
| KalVista Pharmaceuticals, Inc. (KALV) | Director | 6 | 2 legs · 115,686 sh · $1,994,068 | 1 leg · 18,000 sh · $189,050 | 8 |
Insider filings — Cha Albert
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-15 | 4 | Frazier Life Sciences Acquisition Corp. II (FLSC) jointly with Frazier Life Sciences Holdings II LLC, Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C. | Purchase (P): 300,000 @ $10 | EDGAR |
| 2026-10-13 | 3 | Frazier Life Sciences Acquisition Corp. II (FLSC) jointly with Frazier Life Sciences Holdings II LLC, Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C. | Holdings only — no transactions reported | EDGAR |
| 2023-09-28 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-09-13 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,000 @ $6.71 · Option exercise (M): 12,000 @ $7.88 · Sale (S): 18,000 @ $10.50 · Option exercise (M): 6,000 (derivative) @ $0 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2022-10-17 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-10-01 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2020-11-03 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Purchase (P): 68,255 @ $17.17 · Purchase (P): 47,431 @ $17.34 | EDGAR |
| 2020-10-02 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1397906 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs